Highly potent HCV NS4B inhibitors with activity against multiple genotypes
Related Experiment Video
Updated: May 3, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Barton Phillips1, Ruby Cai, William Delaney
1Gilead Sciences , 333 Lakeside Drive, Foster City, California 94404, United States.
Abstract:
The exploration of novel inhibitors of the HCV NS4B protein that are based on a 2-oxadiazoloquinoline scaffold is described. Optimization to incorporate activity across genotypes led to a potent new series with broad activity, of which inhibitor 1 displayed the following EC50 values: 1a, 0.08 nM; 1b, 0.10 nM; 2a, 3 nM; 2b, 0.6 nM, 3a, 3.7 nM; 4a, 0.9 nM; 6a, 3.1 nM.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Subviral Agents
Inhibitors of Bacterial DNA Synthesis
Retrovirus Life Cycles
Viral Hepatitis I: Introduction

